<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697304</url>
  </required_header>
  <id_info>
    <org_study_id>1381-0009</org_study_id>
    <secondary_id>2018-002344-81</secondary_id>
    <nct_id>NCT03697304</nct_id>
  </id_info>
  <brief_title>Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours.</brief_title>
  <official_title>An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in adults with various types of advanced cancer. The purpose of the study is&#xD;
      to test a medicine called BI 754091 in combination with several other cancer medicines. BI&#xD;
      754091 is an immunotherapy. This means it may help the immune system fight cancer. Such&#xD;
      therapies are also called immune checkpoint inhibitors.&#xD;
&#xD;
      How long the participants are in the study depends on whether they benefit from treatment and&#xD;
      whether they experience unacceptable side effects. The participants are put into different&#xD;
      groups.&#xD;
&#xD;
      Each group receives BI 754091 in combination with another medicine.&#xD;
&#xD;
      The doctors check whether the tumors shrink or disappear. The doctors also check the general&#xD;
      health of the participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the trial is objective response (OR), defined as best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the Investigator</measure>
    <time_frame>Up to 32 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR), defined as the time from first documented CR or PR (RECIST v1.1) until the earlier of disease progression or death among patients with OR</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control (DC), defined as best overall response of CR, PR, or stable disease (SD) according to RECIST v1.1 as assessed by the Investigator</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS), defined as the time from first treatment until PD or death from any cause, whichever occurs earlier</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Module A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Module A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Module A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 - Module C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Module C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Module C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - Module C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 - Module C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 754091</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Cohort 1 - Module A</arm_group_label>
    <arm_group_label>Cohort 1 - Module C</arm_group_label>
    <arm_group_label>Cohort 2 - Module A</arm_group_label>
    <arm_group_label>Cohort 2 - Module C</arm_group_label>
    <arm_group_label>Cohort 3 - Module A</arm_group_label>
    <arm_group_label>Cohort 3 - Module C</arm_group_label>
    <arm_group_label>Cohort 4 - Module C</arm_group_label>
    <arm_group_label>Cohort 5 - Module C</arm_group_label>
    <other_name>ezabenlimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 754111</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Cohort 1 - Module A</arm_group_label>
    <arm_group_label>Cohort 2 - Module A</arm_group_label>
    <arm_group_label>Cohort 3 - Module A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 836880</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Cohort 1 - Module C</arm_group_label>
    <arm_group_label>Cohort 2 - Module C</arm_group_label>
    <arm_group_label>Cohort 3 - Module C</arm_group_label>
    <arm_group_label>Cohort 4 - Module C</arm_group_label>
    <arm_group_label>Cohort 5 - Module C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Master Protocol:&#xD;
&#xD;
          -  Provision of signed and dated, written Master informed consent form (ICF) prior to any&#xD;
             trial-specific procedures, sampling, or analyses.&#xD;
&#xD;
          -  Patient ≥18 years of age at the time of signature of the ICF.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) score: 0 or 1.&#xD;
&#xD;
          -  Patient must agree to a pre-treatment biopsy (if archival tissue is not available) and&#xD;
             on-treatment tumour biopsy.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks after the start of the treatment according to the&#xD;
             Investigator's judgement.&#xD;
&#xD;
          -  Male or female patients. Women of childbearing potential (WOCBP) and men able to&#xD;
             father a child must be willing and able to use highly effective methods of birth&#xD;
             control (that result in a low failure rate of less than 1% per year when used&#xD;
             consistently and correctly) during trial participation and for at least 6 months after&#xD;
             the last administration of trial medication.&#xD;
&#xD;
        Module A:&#xD;
&#xD;
        - Histologically confirmed diagnosis of one of the following cohorts:&#xD;
&#xD;
          -  Cohort 1 GEC - Locally advanced, unresectable or metastatic gastric adenocarcinoma or&#xD;
             gastro oesophageal adenocarcinoma (GEC) (defined as primary tumour localisation below&#xD;
             the gastro oesophageal junction (GEJ) with prior anti-PD-1 or anti-PD-L1 based treated&#xD;
             tumour.&#xD;
&#xD;
          -  Cohort 2 Patients with secondary resistance to anti-PD-1 or anti-PD-L1 based therapy:&#xD;
             Any advanced or metastatic solid tumour with previously anti-PD-1 or anti-PD-L1 based&#xD;
             treatment who progressed after achieving benefit&#xD;
&#xD;
          -  Cohort 3 Patients with primary resistance to anti-PD-1 or anti-PD-L1 based therapy:&#xD;
             Select advanced or metastatic solid tumour types with previous anti-PD- 1/PD-L1 based&#xD;
             treated tumour without achieving benefit.&#xD;
&#xD;
          -  All patients must have measurable lesions according to RECIST v1.1&#xD;
&#xD;
          -  Patient must agree to pre- and on-treatment tumour biopsies. If archived tumour tissue&#xD;
             is available from the last treatment failure, sections may be supplied instead of a&#xD;
             pre-treatment biopsy.&#xD;
&#xD;
        Module C:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of one of the following cohorts:&#xD;
&#xD;
               -  Cohort 1: GEC: Locally advanced, unresectable or metastatic gastric&#xD;
                  adenocarcinoma or GEC.&#xD;
&#xD;
               -  Cohort 2: Patients with secondary resistance to anti-PD-1 or anti-PD-L1 based&#xD;
                  therapy: Any advanced or metastatic solid tumour (excluding NSCLC and melanoma)&#xD;
                  with previously anti-PD-1 or anti-PD-L1 based treatment which progressed after&#xD;
                  achieving benefit.&#xD;
&#xD;
               -  Cohort 3: Patients with primary resistance to anti-PD-1 or anti-PD-L1 based&#xD;
                  therapy: Select advanced or metastatic solid tumour types with previous&#xD;
                  anti-PD-1/PD-L1 based treated tumour without achieving benefit.&#xD;
&#xD;
               -  Cohort 4: Locally advanced, unresectable or metastatic second line or greater,&#xD;
                  microsatellite stable (MSS) colorectal cancer.&#xD;
&#xD;
               -  Cohort 5: Advanced Endometrial cancer: Endometrial carcinoma that is pMMR&#xD;
                  (Mismatch Repair-Proficient)/MSS and is advanced, recurrent, or persistent and&#xD;
                  has relapsed or is refractory to curative therapy.&#xD;
&#xD;
          -  All patients must have at least one measurable lesion according to RECIST v1.1&#xD;
&#xD;
          -  Further inclusion criteria apply&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Master Protocol:&#xD;
&#xD;
          -  Any investigational treatment anti-tumour treatment within 4 weeks or within 5&#xD;
             half-life periods (whichever is shorter) prior to the initiation of trial treatment.&#xD;
&#xD;
          -  More than one anti-PD-(L)1-based treatment regimen prior to entering study&#xD;
&#xD;
          -  Major surgery ('major' according to the Investigator's assessment) performed within 12&#xD;
             weeks prior to first trial treatment or planned within 12 months after screening,&#xD;
             e.g., hip replacement.&#xD;
&#xD;
          -  Known history of severe hypersensitivity reactions to other mAbs or known&#xD;
             hypersensitivity to the trial drugs or their excipients.&#xD;
&#xD;
          -  Presence of central nervous system (CNS) metastases, unless treated and asymptomatic&#xD;
             and off corticosteroids and/or anticonvulsant therapy for at least 2 weeks prior to&#xD;
             start of treatment.&#xD;
&#xD;
          -  Immunosuppressive corticosteroid doses (&gt;10 mg prednisone daily or equivalent) within&#xD;
             4 weeks prior to the first dose of study treatment.&#xD;
&#xD;
          -  Active autoimmune disease or a documented history of autoimmune disease, except&#xD;
             vitiligo or resolved childhood asthma/atopy. Patients who were permanently&#xD;
             discontinued from previous anti-PD-1 or anti-PD-L1 therapy because of a immune-related&#xD;
             adverse event (irAE).&#xD;
&#xD;
        Module A:&#xD;
&#xD;
        - Previous treatment with an anti-LAG-3 Agent&#xD;
&#xD;
        Module C:&#xD;
&#xD;
          -  Unresolved, Grade &gt;1 toxicity before the start of treatment with the study drug except&#xD;
             for hair loss (alopecia) and hypothyroidism that requires thyroid hormone supplements&#xD;
             but is asymptomatic under therapy.&#xD;
&#xD;
          -  Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension,&#xD;
             unstable angina, history of infarction within past 6 months, congestive heart failure&#xD;
             &gt; New York Heart Association [NYHA] II)&#xD;
&#xD;
          -  History of severe haemorrhagic or thromboembolic event in the past 12 months&#xD;
&#xD;
          -  Known inherited predisposition to bleeding or to thrombosis, in the opinion of the&#xD;
             investigator - Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shumei Kato</last_name>
      <phone>+001(858)657-7000</phone>
      <email>smkato@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivor Percent</last_name>
      <phone>+001(239)274-9930</phone>
      <email>ipercent@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maen Hussein</last_name>
      <phone>+001(727)216-1143</phone>
      <email>mhussein@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viralkumar Bhanderi</last_name>
      <phone>+1850877-8166</phone>
      <email>vbhanderi@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - East</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Gersten</last_name>
      <phone>561-366-4100</phone>
      <email>tgersten@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Durm</last_name>
      <phone>+1317656-4260</phone>
      <email>gdurm@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Hamm</last_name>
      <phone>+001(502)629-2500</phone>
      <email>john.hamm@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma University School of Community Medicine</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Ulahannan</last_name>
      <phone>+001(405)271-8778</phone>
      <email>Susanna-Ulahannan@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Arrowsmith</last_name>
      <phone>+001(423)7027897</phone>
      <email>earrowsmith@tnonc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Spigel</last_name>
      <phone>+001(615)329-7274</phone>
      <email>dspigel@tnonc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College Of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepak Kilari</last_name>
      <phone>+001(414)805-6700</phone>
      <email>dkilari@mcw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute (University of Alberta)</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quincy Chu</last_name>
      <phone>780-432-8248</phone>
      <email>Quincy.Chu@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Hansen</last_name>
      <phone>416-946-4501ext.2479</phone>
      <email>aaron.hansen@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Evans</last_name>
      <phone>01413017000</phone>
      <email>j.evans@beatson.gla.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Spicer</last_name>
      <phone>02071884260</phone>
      <email>james.spicer@kcl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrik-Tobias Arkenau</last_name>
      <phone>+442032195200</phone>
      <email>tobias.arkenau@hcahealthcare.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Forster</last_name>
      <phone>02076769265</phone>
      <email>martin.forster@ucl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Carter</last_name>
      <phone>+44(0)1619182388</phone>
      <email>louise.carter@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;. Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

